ALK and non-small cell lung carcinoma: Collectively, the decreased clinical efficacy of ALK-TKIs for patients with FGFR1high and FGF2high was consistent with our nonclinical results in FGFR1high and FGF2high NCI-H2228 and FGFR1low and FGF2low SNU-2535 cells, suggesting that basal FGFR1high and FGF2high ALK + NSCLC tumors are associated with worse PFS in patients who received ALK-TKIs as a first-line treatment.